Health ❯ Healthcare ❯ Diabetes

Type 2 Diabetes

Treatment Options GLP-1 Receptor Agonists Semaglutide Medication Management Medication Mounjaro Blood Sugar Management GLP-1 Medications Management Strategies Medications GLP-1 Treatment GLP-1 Treatments Tirzepatide Diabetes Management Prediabetes Blood Sugar Control Weight Loss Treatments Weight Management Ozempic Obesity Management Insulin Delivery Systems Sex Differences in Diabetes Incretin-Based Therapies Insulin Regulation Insulin Testing Treatment Guidelines Blood Testing Health Technology Medication Access Medications for Diabetes Insulin Resistance Diagnosis Errors Mounjaro Usage Management Management of Type 2 Diabetes Pediatric Treatment Patient Behavior Youth Treatments HbA1c GLP-1 Agonists Pediatric Type 2 Diabetes Treatment Strategies Complications SGLT2 Inhibitors Insulin Sensitivity Treatment Methods Diabetes Medications Insulin Lifestyle Interventions NHS Treatments Incretin Drugs Pre-diabetes Oral Medications Insulin Efsitora Alfa Efsitora Alfa Medication Use in Children Medication Effects Weight Loss Medications GLP-1 Drugs Medication for Weight Loss Semaglutid Medication Treatments Blood Sugar Regulation Glycemic Control Diabetes Prevention Medication Efficacy Insulin Management Drug Efficacy Diabetic Retinopathy

Meta-Analysis Finds GLP-1 Drugs Show Little Short-Term Impact on Obesity-Linked Cancer Risk

Researchers urge multi-year, cancer-focused trials to determine long-term effects.

Stopping GLP-1 Weight-Loss Drugs Before Pregnancy Linked to Higher Gestational Risks, Study Finds

Lancet Phase 3 Trial Shows Oral GLP-1 Orforglipron Aids Weight Loss and Diabetes Control

JAMA Meta-Analyses at Kidney Week Back Routine SGLT2 Inhibitors Across Kidney Function

Lilly to Launch Late-Stage Trials of Amylin Obesity Drug After 20% Weight Loss in Mid-Stage Study

Lilly’s Oral GLP-1 Orforglipron Beats Farxiga and Placebo in Two Phase 3 Diabetes Trials

Costco to Offer Ozempic and Wegovy for $499 a Month to Self-Pay Members Nationwide

Phase 3 Trials Show Greater Weight Loss With 7.2 mg Injection and 25 mg Oral Semaglutide

Cue-Driven Eaters Lose More Weight on GLP-1 Drugs, Japanese Study Finds

Bariatric Surgery Outperforms GLP-1 Medicines Over 10 Years for Patients With Diabetes and Obesity

Half of Semaglutide Users Quit Within a Year as Higher Dose Trials Show Bigger Losses, More Side Effects

JAMA Studies Find Rare Optic-Nerve Risks With Semaglutide and Tirzepatide

Researchers Plan Trials to Counteract Sucralose’s Impairment of Cancer Immunotherapy

GLP-1 Weight-Loss Drugs Linked to Testosterone Normalization in Men

Amgen Advances Monthly Obesity Drug to Phase 3 After 20% Weight Loss in Mid-Stage Trial

Novo Nordisk’s Amycretin Achieves Up to 24% Weight Loss as It Advances to Phase 3

Eli Lilly’s Oral GLP-1 Pill Matches Injectables in Weight and Blood Sugar Control

Real-World GLP-1 Therapy Yields Lower Weight Loss, Spurs Tetra-Receptor Drug Research